{"id":22728,"date":"2024-02-19T13:19:37","date_gmt":"2024-02-19T12:19:37","guid":{"rendered":"https:\/\/ggba.swiss\/?p=22728"},"modified":"2024-02-19T13:19:39","modified_gmt":"2024-02-19T12:19:39","slug":"alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/","title":{"rendered":"Alys Pharmaceuticals launches in Geneva with USD 100 million investment"},"content":{"rendered":"\n

Alys Pharmaceuticals<\/a> emerged from the consolidation of Aldena Therapeutics, Granular Therapeutics, Klirna Biotech\u2014with substantial operations and staff in Switzerland\u2014Graegis Pharmaceuticals, Nira Biosciences, and Vimela Therapeutics. This strategic amalgamation furnishes Alys with 14 active programs poised to deliver breakthroughs in dermatology, particularly in areas like atopic dermatitis, vitiligo, and more.<\/p>\n\n\n\n

This biotech powerhouse not only boasts a formidable pipeline but is also keen on expanding its portfolio through innovative platforms covering inflammatory and autoimmune diseases, dermatology supportive care for cancer patients, and rare dermatoses. Over the next three years, Alys aims to achieve seven to ten clinical Proof-of-Concept readouts, with at least one program progressing to registrational studies.<\/p>\n\n\n\n

At the forefront of dermatological innovation<\/h4>\n\n\n\n

With a substantial USD 100 million investment from Medicxi<\/a>, Alys, straddling Boston and Geneva, is set to redefine dermatological treatment across several conditions. A significant portion of the company\u2019s operations will unfold in Switzerland, incorporating a wide range of biotech work from R&D to regulatory affairs. Aldena Therapeutics, an Alys affiliate, collaborates with EMPA<\/a> under an Innosuisse grant to advance core technologies. Moreover, Alys’s Swiss team, expected to expand as programs advance, is bolstered by local consultants and R&D service companies.<\/p>\n\n\n\n

The formation of Alys is the brainchild of Medicxi, alongside dermatology luminaries like John Harris, Brian Kim, and Nobel Prize laureate Craig Mello, among others.<\/p>\n\n\n\n

Francesco De Rubertis, a partner at Medicxi and the incoming Chairman of Alys, lauded the merger, highlighting the strategic advantage of pooling diverse assets and easing capital access. This venture not only signifies a new chapter in immuno-dermatology but also reinforces Geneva\u2019s position as a  global biotech hub.<\/p>\n","protected":false},"excerpt":{"rendered":"

A newly established biotech entity, Alys Pharmaceuticals, merges the power of six Medicxi biotech firms to spearhead innovation in immuno-dermatology.<\/p>\n","protected":false},"author":6,"featured_media":22729,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,890,918,902],"class_list":["post-22728","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-healthcare","tag-investment","tag-personalized-medicine"],"acf":[],"yoast_head":"\nAlys launches in Geneva with USD 100 million investment | GGBa<\/title>\n<meta name=\"description\" content=\"A newly established biotech entity, Alys Pharmaceuticals, merges the power of six Medicxi biotech firms to innovate in immuno-dermatology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alys launches in Geneva with USD 100 million investment | GGBa\" \/>\n<meta property=\"og:description\" content=\"A newly established biotech entity, Alys Pharmaceuticals, merges the power of six Medicxi biotech firms to innovate in immuno-dermatology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-19T12:19:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-19T12:19:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Alys Pharmaceuticals launches in Geneva with USD 100 million investment\",\"datePublished\":\"2024-02-19T12:19:37+00:00\",\"dateModified\":\"2024-02-19T12:19:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/\"},\"wordCount\":284,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg\",\"keywords\":[\"Biotech\",\"Healthcare\",\"Investment\",\"Personalized Medicine\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/\",\"url\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/\",\"name\":\"Alys launches in Geneva with USD 100 million investment | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg\",\"datePublished\":\"2024-02-19T12:19:37+00:00\",\"dateModified\":\"2024-02-19T12:19:39+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"A newly established biotech entity, Alys Pharmaceuticals, merges the power of six Medicxi biotech firms to innovate in immuno-dermatology.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"This significant financial backing underscores the potential of Alys's comprehensive pipeline targeting a broad spectrum of dermatological indications, from atopic dermatitis to psoriasis. | \u00a9 Alys Pharmaceuticals\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alys Pharmaceuticals launches in Geneva with USD 100 million investment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alys launches in Geneva with USD 100 million investment | GGBa","description":"A newly established biotech entity, Alys Pharmaceuticals, merges the power of six Medicxi biotech firms to innovate in immuno-dermatology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/","og_locale":"en_US","og_type":"article","og_title":"Alys launches in Geneva with USD 100 million investment | GGBa","og_description":"A newly established biotech entity, Alys Pharmaceuticals, merges the power of six Medicxi biotech firms to innovate in immuno-dermatology.","og_url":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-02-19T12:19:37+00:00","article_modified_time":"2024-02-19T12:19:39+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Alys Pharmaceuticals launches in Geneva with USD 100 million investment","datePublished":"2024-02-19T12:19:37+00:00","dateModified":"2024-02-19T12:19:39+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/"},"wordCount":284,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg","keywords":["Biotech","Healthcare","Investment","Personalized Medicine"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/","url":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/","name":"Alys launches in Geneva with USD 100 million investment | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg","datePublished":"2024-02-19T12:19:37+00:00","dateModified":"2024-02-19T12:19:39+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"A newly established biotech entity, Alys Pharmaceuticals, merges the power of six Medicxi biotech firms to innovate in immuno-dermatology.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg","width":2360,"height":1622,"caption":"This significant financial backing underscores the potential of Alys's comprehensive pipeline targeting a broad spectrum of dermatological indications, from atopic dermatitis to psoriasis. | \u00a9 Alys Pharmaceuticals"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Alys Pharmaceuticals launches in Geneva with USD 100 million investment"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/22728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=22728"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/22728\/revisions"}],"predecessor-version":[{"id":22732,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/22728\/revisions\/22732"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/22729"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=22728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=22728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=22728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}